TY - JOUR T1 - Determining the burden of infectious diseases caused by carbapenem-resistant gram-negative bacteria in Spain JO - Enfermedades Infecciosas y Microbiología Clínica T2 - AU - Cantón,Rafael AU - Huarte,Rafael AU - Morata,Laura AU - Trillo-Mata,José Luís AU - Muñoz,Rocío AU - González,Javier AU - Tort,Marina AU - Badia,Xavier SN - 0213005X M3 - 10.1016/j.eimc.2020.04.009 DO - 10.1016/j.eimc.2020.04.009 UR - https://www.elsevier.es/es-revista-enfermedades-infecciosas-microbiologia-clinica-28-articulo-determining-burden-infectious-diseases-caused-S0213005X20301919 AB - ObjectiveTo estimate the burden of nosocomial infections induced by carbapenem resistant Gram-negative (CRGN) pathogens in Spain, focusing on both the clinical and economic impact. MethodsThe burden of disease was estimated using data from 2017 according to the availability of data sources. The impact, both clinical and economic, of the most frequent CRGN nosocomial infections (those produced by Klebsiella pneumoniae, Pseudomonasaeruginosa and Acinetobacter baumannii) was analysed. Incidence and mortality of CRGN nosocomial infections were estimated, as well as the direct and indirect costs produced by this health problem. ResultsApproximately 376,346 patients are believed to have suffered a nosocomial infection in Spain in 2017; 3.2% of them due to CRGN bacilli. Infections by carbapenem-resistant P. aeruginosa produced the highest mortality rates (2578 deaths) when compared with A. baumannii (1571) and K. pneumoniae (415). Total economic costs of CRGN nosocomial infections in Spain were estimated to be €472 million in 2017, with 83% of the total cost caused by direct costs. ConclusionCRGN nosocomial infections have a high clinical impact on patients’ lives, high mortality rates, and represent one of the hospitalisation episodes with the most associated costs. Efforts should be focussed to implement preventive policies in order to avoid infections due to CRGN pathogens and the resulting burden, and to reduce direct costs due to morbimortality, specifically in those infections produced by P. aeruginosa. ER -